No clinician-patient relationship is formed through this content.
In the STEP 1 extension trial, participants regained two-thirds of their lost weight within 12 months of stopping semaglutide (Wilding et al., Diabetes Obes Metab 2022)
Participants reported improvements in mobility, physical activity capacity, and energy levels throughout treatment despite substantial weight reduction
They suspect that both cost and negative side effects cause people to stop using the drugs
It is a type of glucagon-like peptide-1 (GLP-1) receptor agonist, which works by mimicking an intestinal hormone that reduces appetite and improves insulin secretion
The prefrontal cortex, which governs executive function and impulse control, shows altered glutamate dynamics following GLP-1 agonist administration